Overview

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.

Status:
Completed

Trial end date:
2020-08-28

Target enrollment:

Participant gender:

Summary

To evaluate the safety, efficacy and pharmacokinetics of nilotinib over time in the Ph+ chronic myelogenous leukemia (CML) in pediatric patients (from 1 to <18 years).

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborators:

Children's Oncology Group
Innovative Therapies For Children with Cancer Consortium